Current Pharmaceutical Biotechnology - Online First

This study aims to examine the impact of Rukangyin (RKY) and its components, LSQR and QTSS, on various cellular processes and signaling mechanisms in MDA-MB-231 triple-negative breast cancer (TNBC) cells.

Twenty-five Sprague-Dawley (SD) rats were randomly assigned to five groups according to the administered drugs, including the RKY group, LSQR group, QTSS group, fluorouracil group, and blank control group (n=5 in each group). The serum samples from each group were then used as a medicated medium for the culture of the TNBC cell line MDA-MB-231. Cell viability tests, apoptosis detection tests, and migration and invasion tests were used to evaluate the cytotoxicity of treated serum. YAP, TAZ, MST1, and LATS1 protein expression and phosphorylation were examined using conventional western blotting methods.

RKY and its QTSS and LSQR components significantly inhibited cell growth and promoted apoptosis in MDA-MB-231 cells. RKY also significantly blocked cell motility with a comparable effect to that of fluorouracil. All serum groups suppressed YAP and TAZ expressions while increasing p-YAP, p-TAZ, MST1, and LATS1 levels, with RKY showing superior efficacy.

In TNBC cells, RKY appears to enhance the tumor-suppressing signals of the Hippo signaling pathway via MST1, LATS1 activation, while restricting its pro-oncogenic action via YAP and TAZ blockade. However, in vivo and animal model experiments are required to confirm these findings.

RKY-medicated serum effectively inhibits growth, induces apoptosis, and reduces motility in the MDA-MB-231 cell line of breast cancer. This therapeutic potential of RKY on TNBC cells draws attention to the need for more investigations.

Cardiovascular diseases (CVDs) are the leading cause of death globally, often complicated by thromboembolic events. Plasmin, a key enzyme in fibrinolysis, is crucial for managing these conditions. Elevated or reduced plasmin levels can indicate thrombotic risks, making it a valuable diagnostic marker. Recent biotechnological advances have developed diagnostic kits to measure plasmin activity, aiding early detection and intervention. Fungal proteases, particularly from micromycetes, are emerging as promising agents in anticoagulant therapy. This study investigates three Aspergillus species — A. caespitosus, A. jensenii and A. neotritici for their potential to produce novel biomedical components.

The fungi were cultured, and their proteolytic profiles were analyzed. Key findings include the identification of specific proteases with plasmin-like and protein C-activating activities. These enzymes were purified using isoelectric focusing and characterized through SDS-PAGE and zymography.

The study confirmed that A. jensenii, and A. neotritici produce proteases with plasmin-like activity, with A. neotritici showing a single 35 kDa non-specific protease, and A. jensenii exhibiting two proteases (33 kDa and 100 kDa) in the acidic zone and one (110 kDa) in the neutral zone, the latter exhibiting specific chymotrypsin and plasmin-like activity.

Among the studied strains, A. neotritici exhibited the fastest secretion of proteases with plasmin-like activity, making it a promising source of enzymes with potential clinical applications. In contrast, A. caespitosus and A. jensenii displayed more complex protease compositions, featuring multiple active enzymes. Notably, one of the A. jensenii proteases showed pronounced specificity toward chymotrypsin and fibrinolytic substrates, indicating its suitability for the development of targeted therapeutic agents.

These findings suggest the potential of these fungal proteases for developing novel anticoagulant therapies and diagnostic tools.

Breast cancer (BC) represents a malignancy affecting populations globally. Its incidence is on the rise. The ethanolic extract of Cyperus rotundus (EECR) has demonstrated potent anticancer activities against multiple human cancer types, inducing apoptosis in BC cells. Autophagic flux protects HER2+ cancer cells from trastuzumab-induced cytotoxicity, so inhibiting it undermines the resistance phenotype. This study aimed to elucidate the therapeutic potential of EECR in trastuzumab-resistant HER2-positive BC and decipher its underlying mechanisms.

Colony formation assay and Cell Counting Kit-8 (CCK-8) assessed cell viability. Flow cytometry was used for cell cycle analysis and apoptosis detection. Western blotting quantified relevant protein expressions. Nude mice were euthanized prior to tissue harvest. Tumor tissues were excised and processed for histological examination, with 5 μm paraffin sections prepared on glass slides for hematoxylin and eosin (H&E) staining. An orthotopic JIMT-1 cell transplantation tumor model was established, and immunohistochemistry was conducted.

EECR demonstrated a dose-dependent suppressive effect on HER2-positive BC cells, inducing apoptosis and G2-M phase cell cycle arrest. It inhibited autophagic flux, as evidenced by LC3 and p62/SQSTM1 accumulation, and upregulated raptor and phosphorylated Mitogen-Activated Protein Kinase (MAPK) in trastuzumab-resistant JIMT-1 cells. Phosphorylated ERK (pERK)/total ERK and Raptor levels were significantly elevated in EECR-treated JIMT-1 cells compared to other treatment groups. Furthermore, EECR significantly inhibited tumorigenic growth in JIMT-1 cells.

This study reveals that EECR effectively impedes autophagic flux in trastuzumab-resistant HER2-positive breast cancer cells, a mechanism increasingly recognized as central to therapeutic resistance. By promoting LC3B and p62 accumulation and modulating the MAPK/mTOR signaling axis, EECR not only disrupts a key survival pathway in resistant cells but also enhances the efficacy of standard chemotherapeutic agents like docetaxel. These dual effects—autophagy inhibition and chemosensitization—underscore EECR’s therapeutic potential as an adjuvant strategy to overcome trastuzumab resistance. Given its multi-target nature and favorable safety profile, EECR represents a promising candidate for future combination therapy in refractory HER2-positive breast cancer.

In view of the increasing resistance of Candida species, it is necessary to explore alternative strategies. In this context, essential oils have emerged as promising options, among which the essential oil of Astronium urundeuva (M. Allemão) Engl. has shown potential, as it is traditionally used in folk medicine for the treatment of inflammation and multiple infections. Thus, the aim of this study was to evaluate the chemical profile, anti-Candida activity, and Fluconazole (FCZ) potentiating effect of the essential oil extracted from the leaves of A. urundeuva (EOAU) and its ability to inhibit the virulence mechanism in Candida species.

The essential oil was obtained via hydrodistillation and characterized using gas chromatography-mass spectrometry. To evaluate the antifungal effects and the modulating activity of Fluconazole (FCZ), the essential oil was diluted in DMSO (1 mL) and SDB medium (9 mL) and tested on 3 Candida strains using the serial microdilution method. In addition, a morphological transition assay was used to evaluate its capacity to inhibit fungal virulence.

The major constituent of EOAU was the monoterpene β-myrcene (71.07%). The results indicate that the essential oil exhibits an antifungal effect, with C. tropicalis being the most susceptible species. At subinhibitory concentrations (MC/8), the EOAU enhanced the action of fluconazole against C. krusei and C. tropicalis. The EOAU strongly inhibited the morphological transition in C. tropicalis.

EOAU is rich in β-myrcene and exhibits an interesting fungistatic effect, making it a great natural candidate for inhibiting Candida spp. virulence.

The crystallization of heme into β-hematin and its subsequent conversion to hemozoin has garnered significant interest as a promising target for the development of novel antimalarial therapies, particularly through the heme detoxification pathway. Furthermore, the therapeutic efficacy of chloroquine (CQ) has been widely recognized, with several studies highlighting its role as an inhibitor of β-hematin and hemozoin formation.

This study reports the synthesis of two novel CQ-derived compounds, 7-chloroquinolin-4-amine (CQC1) and 7-chloro-4-(¹-oxidaneyl)-3,4-dihydroquinoline (CQC2), and evaluates their individual inhibitory effects on β-hematin formation.

Notably, comparative analysis of the experimental data revealed significant variability in the IC50 values for these compounds, which correspond to the concentration required to inhibit 50% of β-hematin synthesis. The impact of incubation time and compound concentration on IC50 values was also investigated.

The findings suggest that increasing the concentration and incubation time of both CQ derivatives led to a reduction in their IC50 values, with both compounds demonstrating enhanced inhibitory activity relative to commercial chloroquine (CQ).

Bacterial cellulose, which is used in many fields from biomedicine to electronics, is promising as an alternative wound dressing instead of traditional gauze in wound treatment.

The objective of this study was to evaluate the potential use of cellulose produced by acetic acid bacteria isolated from rotten fruits as a wound dressing.

In our study, rotten fruit samples were incubated in Hestrin-Schramm (HS) Broth medium. Then, a loopful of the pellicle-forming samples was taken and inoculated onto Hestrin-Schramm (HS) agar using the streak culture method and bacteria were isolated. Identification of bacteria was performed using the BLAST program after 16S rRNA sequence analysis. Physicochemical properties and morphological characterization of bacterial cellulose produced by static culture were examined using Fourier transform infrared (FTIR) and scanning electron microscopy (SEM), respectively, and the swelling ratio was investigated. Antibiotic susceptibilities of bacterial cellulose membranes impregnated with different concentrations of gentamicin (50 µg/mL, 100 µg/mL, 200 µg/mL) against Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 were determined by the disk diffusion method.

The bacteria isolated from rotten fruits were identified as Acetobacter tropicalis NBRC 16470. The structure of cellulose produced by static culture was confirmed by a peak at 3,240 cm⁻¹ in FTIR analysis and fibril structures in SEM analysis. Bacterial cellulose had a swelling ratio of 27.37± 2 .99 fold. The zone diameters formed by bacterial cellulose disk (50 µg/mL gentamicin) and gentamicin (10 µg) disk against Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 were almost the same.

The production of bacterial cellulose, which has the potential to be used as a wound dressing from rotten fruits, is important in terms of recycling and low cost.

The combination of Gardeniae Fructus (ZZ) and Scutellariae Radix (HQ) is a traditional Chinese medicine used for Alzheimer’s disease (AD). However, the molecular mechanisms underlying its anti-dementia effects, particularly its multi-component synergy and pathway modulation, remain poorly understood.

Our study employed an integrated systems pharmacology approach to mechanistically decode the anti-AD properties of ZZ-HQ, combining network pharmacology predictions, molecular docking simulations, and experimental validation to identify critical bioactive components, molecular targets, and therapeutic pathways.

A comprehensive network pharmacology analysis was performed to identify bioactive compounds within the ZZ-HQ complex and their potential protein targets associated with AD. Molecular docking was utilized to predict and assess the binding interactions between key bioactive compounds and AD-related protein targets. Experimental validation focused on baicalin, a major active compound in the ZZ-HQ complex, evaluating its effects on cell viability, apoptosis regulation, oxidative stress reduction, and the activation of the PI3K/Akt signaling pathway.

Fifty-four bioactive compounds were identified in the ZZ-HQ complex, interacting with 258 AD-associated proteins. Key compounds, such as baicalein and norwogonin, demonstrated strong binding affinities with pivotal proteins, including SRC and PIK3R1. Experimental studies further confirmed that baicalin significantly improved cell viability by activating the PI3K/Akt pathway, reducing apoptosis, and alleviating oxidative stress.

Our study uncovered the therapeutic potential of the ZZ-HQ combination in addressing AD through multi-target mechanisms, particularly via modulation of the PI3K/Akt pathway and oxidative stress. These findings provide a scientific basis for the pharmacological effects of ZZ-HQ and offer valuable insights for further research on its potential application in AD treatment.

Oropharyngeal candidiasis (OPC), a fungal infection affecting the mouth and throat, imposes a substantial burden on vulnerable populations such as HIV/AIDS patients, cancer treatment recipients, and the elderly. Conventional antifungal medications are encountering increasing resistance and side effects, necessitating the exploration of novel therapeutic approaches.

This review proposes a comprehensive strategy for developing a novel natural product-based antifungal formulation targeting OPC. The approach involves harnessing promising natural compounds with established antifungal properties and employing advanced delivery systems like mucoadhesive microemulsions to improve efficacy and minimize adverse effects. Additionally, the review explores the integration of computational methods to expedite the identification and development of potent antifungal agents.

A comprehensive literature review was conducted using databases such as PubMed, Scopus, and Web of Science. Search terms included combinations of “oropharyngeal candidiasis,” “natural antifungal agents,” “flavonoids,” “mucoadhesive microemulsions,” “computational drug discovery,” and “in vitro/in vivo studies.” Priority was given to studies published within the last ten years.

The review identifies promising natural compounds with antifungal activity against Candida species commonly associated with OPC. Additionally, several studies highlight the potential of computational tools such as molecular docking and in silico ADMET for rapidly identifying natural compounds with potent antifungal activity and favorable pharmacokinetic and safety profiles. A brief overview of in vitro and in vivo experiments is provided, emphasizing their role in validating the safety and efficacy of the proposed natural product-based antifungal formulation. Formulation and analytical aspects are also discussed.

The multidisciplinary approach outlined, incorporating natural products, computational methods, advanced preclinical in vitro and in vivo experiments, and advanced delivery systems, offers promise for the rapid, cost-effective development of safe and effective optimized formulations to address the growing challenge of OPC, particularly in vulnerable populations.